Evgen Pharma PLC Grant of Options - Director/PDMR Shareholding (7510J)
14 Diciembre 2022 - 11:08AM
UK Regulatory
TIDMEVG
RNS Number : 7510J
Evgen Pharma PLC
14 December 2022
Evgen Pharma plc
("Evgen" or the "Company")
Grant of Options
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company developing sulforaphane-based medicines announces that , on
14 December 2022, certain employees and directors of the Company,
including the following Persons Discharging Managerial
Responsibility ("PDMR"), were granted nil cost options (the
"Options") over a total of 11,122,199 ordinary shares of 0.25 pence
each in the Company ("Ordinary Shares"), exercisable, subject to
the Options vesting, for a period of up to 10 years from the date
of grant and governed by the rules of the Evgen Pharma plc Long
Term Incentive Plan ("LTIP").
PDMR Position Current Ordinary Current Options held New options granted % of issued share
Shares held capital including
this award
--------------------
Dr Huw Jones CEO 62,500 4,648,890 4,410,727 3.3%
---------- --------------------- -------------------- --------------------
Richard Moulson CFO 45,454 889,728 1,460,855 0.9%
---------- --------------------- -------------------- --------------------
The Options will vest on the third anniversary of grant based on
performance against challenging
strategic corporate objectives over three years (40%), share
price growth (30%) and on an elapsed time basis at 3 years
(30%).
Following this award there are 21,361,574 options in issue,
representing 7.8% of the Company's issued share capital.
Enquiries:
Evgen Pharma plc
Dr Huw Jones, CEO
Richard Moulson, CFO +44 1625 466591
FinnCap (Nominated Advisor and
Broker)
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane/Nigel Birks (ECM) +44 20 7220 0500
Instinctif Partners +44 207 457 2020
Melanie Toyne-Sewell / Rozi Morris Evgen@Instinctif.co
/ Agnes Stephens / Adam Loudon
The information contained within this announcement is deemed to
constitute inside information as stipulated under the retained EU
law version of the Market Abuse Regulation (EU) No. 596/2014 (the
"UK MAR") which is part of UK law by virtue of the European Union
(Withdrawal) Act 2018. The information is disclosed in accordance
with the Company's obligations under Article 17 of the UK MAR.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Huw Jones
----------------------------------------------------------- ---------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status CEO
----------------------------------------------------------- ---------------------------------------------------
b) Initial notification /Amendment Initial Notification
----------------------------------------------------------- ---------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name Evgen Pharma Plc
----------------------------------------------------------- ---------------------------------------------------
b) Legal Entity Identifier 213800NO3E6TSTQO8K20
----------------------------------------------------------- ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Options over Ordinary Shares of 0.25 pence each
instrument GB00BSVYN304
Identification code
----------------------------------------------------------- ---------------------------------------------------
b) Nature of the transaction Grant of options
----------------------------------------------------------- ---------------------------------------------------
c) Currency GBP
----------------------------------------------------------- ---------------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
----------------------------------------------------------- ------------------------- ------------------------
nil 4410727
------------------------------------------------------------------------------------------ ------------------------
e) Aggregated information
- Aggregated volume As above
- Price
- Aggregated total
----------------------------------------------------------- ---------------------------------------------------
f) Date of the transaction 14 December 2022
----------------------------------------------------------- ---------------------------------------------------
g) Place of the transaction London Stock Exchange, AIM
----------------------------------------------------------- ---------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Richard Moulson
----------------------------------------------------------- ---------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status CFO
----------------------------------------------------------- ---------------------------------------------------
b) Initial notification /Amendment Initial Notification
----------------------------------------------------------- ---------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name Evgen Pharma Plc
----------------------------------------------------------- ---------------------------------------------------
b) Legal Entity Identifier 213800NO3E6TSTQO8K20
----------------------------------------------------------- ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Options over Ordinary Shares of 0.25 pence each
instrument GB00BSVYN304
Identification code
----------------------------------------------------------- ---------------------------------------------------
b) Nature of the transaction Grant of options
----------------------------------------------------------- ---------------------------------------------------
c) Currency GBP
----------------------------------------------------------- ---------------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
----------------------------------------------------------- ------------------------- ------------------------
nil 1460855
------------------------------------------------------------------------------------------ ------------------------
e) Aggregated information
- Aggregated volume As above
- Price
- Aggregated total
----------------------------------------------------------- ---------------------------------------------------
f) Date of the transaction 14 December 2022
----------------------------------------------------------- ---------------------------------------------------
g) Place of the transaction London Stock Exchange, AIM
----------------------------------------------------------- ---------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUSRBRUSUUAAA
(END) Dow Jones Newswires
December 14, 2022 12:08 ET (17:08 GMT)
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024